It is very uncertain whether fluoroquinolone plus standard regimen changes serious adverse events compared with standard regimen alone (very low certainty).
It is very uncertain whether the intervention changes serious adverse events (very low certainty).
It is very uncertain whether day‐surgery changes serious adverse events compared with overnight stay surgery (very low certainty).
It is very uncertain whether miniport laparoscopic cholecystectomy changes serious adverse events compared with standard port laparoscopic cholecystectomy (very low certainty).
It is very uncertain whether intervention changes serious adverse events compared with control (very low certainty).
It is very uncertain whether early changes serious adverse events compared with delayed laparoscopic cholecystectomy (very low certainty).
Topiramate 200 to 400 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Continuous showed no clear difference in serious adverse events compared with intermittent Antibiotic Infusions (low certainty).
Summary of findings: ACT showed no clear difference in serious adverse events compared with CQ (high certainty).
Xiongshao capsule (XSC) plus conventional western medicine (CWM) leads to lower serious adverse events compared with conventional western medicine (CWM) (high certainty).
Xiongshao capsule (XSC) plus conventional western medicine (CWM) leads to lower serious adverse events compared with conventional western medicine (CWM) plus placebo (high certainty).
It is very uncertain whether early changes serious adverse events compared with delayed laparoscopic cholecystectomy (very low certainty).
Pregabalin showed no clear difference in serious adverse events compared with placebo at end of treatment (moderate certainty).
It is very uncertain whether ursodeoxycholic acid changes serious adverse events compared with placebo or no intervention (very low certainty).
TDF+ FTC showed no clear difference in serious adverse events compared with placebo (moderate certainty).
TDF showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Anti‐leukaemic therapy plus alemtuzumab showed no clear difference in serious adverse events compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).
Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with placebo (moderate certainty).